- Home
- CELC vs UTG Comparison
CELC vs UTG Comparison
Compare CELC & UTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- UTG
- Stock Information
- Founded
- CELC 2011
- UTG 2003
- Country
- CELC United States
- UTG United States
- Employees
- CELC N/A
- UTG N/A
- Industry
- CELC Medical Specialities
- UTG Investment Managers
- Sector
- CELC Health Care
- UTG Finance
- Exchange
- CELC Nasdaq
- UTG Nasdaq
- Market Cap
- CELC 3.1B
- UTG 3.3B
- IPO Year
- CELC 2017
- UTG N/A
- Fundamental
- Price
- CELC $100.23
- UTG $37.92
- Analyst Decision
- CELC Strong Buy
- UTG
- Analyst Count
- CELC 7
- UTG 0
- Target Price
- CELC $95.29
- UTG N/A
- AVG Volume (30 Days)
- CELC 916.2K
- UTG 317.8K
- Earning Date
- CELC 11-12-2025
- UTG 01-01-0001
- Dividend Yield
- CELC N/A
- UTG 7.28%
- EPS Growth
- CELC N/A
- UTG N/A
- EPS
- CELC N/A
- UTG 9.86
- Revenue
- CELC N/A
- UTG $96,107,593.00
- Revenue This Year
- CELC N/A
- UTG N/A
- Revenue Next Year
- CELC N/A
- UTG N/A
- P/E Ratio
- CELC N/A
- UTG $3.20
- Revenue Growth
- CELC N/A
- UTG 8.35
- 52 Week Low
- CELC $7.58
- UTG $25.26
- 52 Week High
- CELC $103.06
- UTG $35.29
- Technical
- Relative Strength Index (RSI)
- CELC 78.25
- UTG 52.73
- Support Level
- CELC $92.10
- UTG $35.81
- Resistance Level
- CELC $103.06
- UTG $37.88
- Average True Range (ATR)
- CELC 5.52
- UTG 0.76
- MACD
- CELC 0.74
- UTG 0.09
- Stochastic Oscillator
- CELC 90.84
- UTG 96.35
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.